diabetes – CRI Report

Investigation Report on China’s Metformin Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Metformin is the first-line drug for the treatment of type 2 diabetes, especially in people who are overweight. Metformin was originally developed by Merck Sharp & Dohme (trade name: GLUCOPHAGE ). GLUCOPHAGE first went on the market in France in 1957 and went on the market in China in 1994. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are several manufactures in China’s Metformin market by 2020, of which Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Metformin in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall medical diagnosis and treatment services, the sales value of Metformin in the Chinese market fell to CNY707 million in 2020, a year-on-year decline of 4.19%. The CAGR of Metformin sales value in the Chinese market from 2016 to 2020 is 7.01%.

CRI expects that with the relief of COVID-19, the sales value of Metformin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the number of diabetic patients in China ranks first in the world. The total prevalence rate of diabetes in adults is 12.8%. Type II diabetes accounts for 90% of diabetic patients, and the number of patients is huge. At the same time, as the population ageing in China is becoming increasingly severe, the number of patients and the prevalence rate are also increasing year by year. Therefore, the sales volume and sales value of Metformin for the treatment of type 2 diabetes have an increasing trend. In addition, compared with similar drugs, Metformin not only has the effect of lowering blood sugar, but also may have the effect of weight loss and treatment of hyperinsulinemia, and it can be effective for patients with poor efficacy of certain sulfonylureas. Based on these advantages, it is expected that the sales value of Metformin in the Chinese market will increase from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Metformin market
– Sales value of China’s Metformin 2016-2020
– Competitive landscape of China’s Metformin market
– Prices of Metformin in China
– Prices of Metformin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Metformin market
– Prospect of China’s Metformin market from 2021 to 2025

The post Investigation Report on China’s Metformin Market 2021-2025 first appeared on CRI Report.

Investigation Report on Chinese Insulin Glargine Market, 2018-2022

admin — Fri, 17 Aug 2018 09:04:56 +0000

Description
With the development of China’s economy, the improvement of residents’ living standard, the change of lifestyle and the aging of population, diabetes is seeing a rising prevalence and has become the third most serious chronic disease that threatens human health next to tumors and cardiovascular diseases.
According to WHO’s data, there are about 110 million diabetics in China, about 1/10 of China’s adults. And the number will increase to 150 million in 2040 if no swift actions are taken to reduce the risk factors such as unhealthy diet and lack of exercises. The rapid growth of diabetes has placed a heavy burden on China’s social and economic development.
Insulin Glargine is the first long-acting insulin produced by simulating recombinant DNA technology. It was approved to be put into use by FDA in Apr. 2000 and then by the European Agency for the Evaluation of Medicinal Products (EMEA) in Jun. 2000. The sales value has been growing since Insulin Glargine entered China and exceeded CNY 800 million in 2017.
In China, the third generation of insulin is still under promotion. Due to the relatively high price, it has not yet dominated the market. The second and third generations of insulin will form a market pattern of dislocation competition.
Because Insulin Glargine is mainly produced by genetic engineering methods, the threshold of production technology is relatively high. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap. Hence manufacturers must attain an industrial production of large scale, low cost and mature technology to gain profits. At present, the Chinese market is dominated by Aventis Behring’s brand-name drug and the generic drugs of Gan & Lee Pharmaceuticals and Zhuhai United Laboratories Co., Ltd. However, it is expected that the market pattern in China will change in the next few years as some domestic enterprises are speeding up the development of generic Lantus.
According to CRI, the incidence of diabetes keeps increasing in China with the improvement of people’s living standard and the change of lifestyle, which expands the diabetes drug market year by year. The market size of diabetes drugs in China exceeded CNY 30 billion in 2017. The third-generation insulin products have been technically improved, reduced some shortcomings of the second-generation products, and effectively shortened the treatment time. They are expected to completely replace the second-generation insulin in the future. It is foreseeable that Insulin Glargine is the product with most growth potential among the three generations of insulin products in China, and its market size will continue to grow from 2018 to 2022.

Topics Covered:
– Development environment of Insulin Glargine
– Supply of and demand for Insulin Glargine in China
– Major Insulin Glargine manufacturers in China
– Prices of Insulin Glargine in China
– Factors influencing the development of the Chinese Insulin Glargine market from 2018 to 2022
– Prospect of the Chinese Insulin Glargine market from 2018 to 2022

The post Investigation Report on Chinese Insulin Glargine Market, 2018-2022 first appeared on CRI Report.

Global Diabetes Monitors Market Analysis & Forecast 2017 To 2023

admin — Fri, 17 Aug 2018 08:40:42 +0000

Diabetes is a chronic disease characterized by elevated levels of blood glucose which leads to serious damage to the heart, eyes, kidneys, blood vessels and nerves. The most common of diabetes is type 2 diabetes which occurs when the body becomes resistant to insulin or doesn’t make enough insulin. In the past three decades the prevalence of type 2 diabetes has risen dramatically in countries of all income levels. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin by itself.
The market of diabetes monitor is increasing due to an increase in the prevalence of diabetes, changing lifestyle and increasing use of insulin for the treatment of diabetes. Increase awareness regarding prevention and treatment of diabetes, and increasing demand for technologically advanced devices for diabetes monitoring.
The global diabetes monitors market is expected to reach USD 17458.1 million by 2023 at a CAGR of 8.3%.
The global diabetes monitors market is segmented on the basis of sample, type, component, and end-users. On the basis of sample, the market is segmented into blood samples, sweat samples, urine samples, and others. On the basis of type, the market is classified into point sample test based glucose monitors, continuous glucose monitors, and enzyme free sensor based glucose monitors. Continuous glucose monitors are further segmented into disposable sensor based CGM, and re-usable sensor based CGM. On the basis of components, the market is classified into lancet, glucose test strips, and sensors. Sensors are further segmented into enzyme-based sensors, and enzyme-free sensors
On the basis of end -users, the market is segmented into diagnostic clinics, hospitals, and home.
Key Players:
The leading players in the global diabetes monitor market are Panasonic, Abbott Laboratories, Dexcom, Inc., F. Hoffmann-La Roche Ltd , Medtronic, LifeScan, Inc., Sanofi, and others.
Study objectives of diabetes Monitor market:
 To provide insights about factors influencing and affecting the market growth
 To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
 To provide historical and forecast revenue of the market segments based on types, products, applications, end users, and its sub-segments.
 To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market

Target Audience:
• Medical devices manufacturers
• Medical devices distributors
• Hospitals & Clinics
• Potential investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings:
• On the basis of sample, blood sample market is expected to command the largest market share of 75.70% over the review period and it is also expected to grow at the fastest CAGR of 8.6% during the forecast period 2017-2023
• Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 8.9% over the 2017-2023
The reports also cover country level analysis:
• America
• North America
• US
• Canada
• Latin America
• Europe
• Western Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest Of Western Europe
• Eastern Europe
• Asia-Pacific
• Japan
• China
• India
• Republic of Korea
• Rest of Asia-Pacific
• Middle East & Africa
• UAE
• Saudi Arabia
• Oman
• Kuwait
• Qatar
• Rest of Middle East & Africa

Table of Contents

1 Report Prologue
1.1 Introduction
2 Introduction
2.1 Research Objective
2.2 Assumptions & Limitations
2.2.1 Assumptions
2.2.2 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.4.1 Trade Analysis
3.4.2 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence and incidence of diabetes mellitus (DM) (Impact Weightage-35%)
4.2.2 Rise in technological innovations (Impact Weightage-30%)
4.2.3 Research funding in diabetes diagnosis and treatment (Impact Weightage-15%)
4.2.4 Rising awareness and screening for Diabetes Mellitus (Impact Weightage-20%)
4.3 Restraints
4.3.1 Stringent reimbursement and insurance policies in developing nations, can hamper the market growth in coming future (Impact Weightage-35%)
4.3.2 High cost associated with diagnosis and treatment of diabetes (Impact Weightage-65%¬)
4.4 Opportunities
4.4.1 Technologically advanced products in the pipeline
4.4.2 Rise in Global Obesity Population
4.4.3 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Raw Material
5.2.2 Supplier
5.2.3 Manufacturer
5.2.4 Distributer
5.2.5 Customer
5.2.6 Consumer
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Diabetes Monitors Market by Sample
6.1 Introduction
6.2 Blood Samples
6.3 Sweat Samples
6.4 Urine Samples
6.5 Others
7 Global Diabetes Monitors Market by Type
7.1 Introduction
7.2 Point sample test based Glucose Monitors
7.3 Continuous glucose monitors
7.4 Enzyme free sensor based Glucose Monitors
8 Global Diabetes Monitors Market by Components
8.1 Introduction
8.2 Lancet
8.3 Glucose test strips
8.4 Sensors
9 Global Diabetes Monitors Market by End Users
9.1 Introduction
9.2 Diagnostic Clinics
9.3 Hospitals
9.4 Home
10 Global Diabetes Monitors Market by Regions
10.1 Introduction
10.2 Americas
10.2.1 US
10.2.2 Canada
10.2.3 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 Middle East & Africa
10.5.1 UAE
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of Middle East & Africa
11 Competitive Landscape
11.1 Introduction
12 Company Profiles
12.1 Panasonic
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Products
12.1.4 Strategy
12.1.5 Key Developments
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Products
12.2.4 Strategy
12.2.5 Key Developments
12.3 Dexcom, Inc.
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Products
12.3.4 Strategy
12.3.5 Key Developments
12.4 F. Hoffmann-La Roche Ltd
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Products
12.4.4 Strategy
12.4.5 Key Developments
12.5 LifeScan, Inc.
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Products
12.5.4 Strategy
12.5.5 Key Developments
12.6 Sanofi
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Products
12.6.4 Strategy
12.6.5 Key Developments
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.2 Key companies to watch
14 Appendix
14.1 Discussion Blue Print

The post Global Diabetes Monitors Market Analysis & Forecast 2017 To 2023 first appeared on CRI Report.